_Market_1.jpg)
The Peptide–Drug Conjugates (PDCs) Market Size is valued at 696.2 Million in 2022 and is predicted to reach 3113.7 Million by the year 2031 at a 18.2 % CAGR during the forecast period for 2023-2031.
The emergence of Peptide–Drug Conjugates (PDCs) therapy for patients suffering from different cancers is believed to create several clinical opportunities during the forecast period. Peptide drug conjugates comprise three vital components: a homing peptide, a linker, and a cytotoxic payload that targets the tumour cell to release the cytotoxin. PDC targets tumour cells with a peptide chain of about ten amino acids, and its molecular weight is smaller than Antibody Drug Conjugates (ADCs), which can be rapidly enriched to tumour sites, while drug molecules in blood can be cleared quickly with a short half-life, helping to reduce toxic side effects caused by off-targeting. Due to the increasef popularity of ADCs, the pharmaceutical industry has been pushed to investigate additional drug conjugates, resulting in the development of a vast array of innovative Conjugated Drugs.
Therapeutic drugs are anticipated to be driven by the rising partnerships, mergers, and acquisitions of market players. The increasing number of pharmaceutical drug innovations is expected to fuel the growth of peptide–drug conjugates (PDCs) market in the near future. Also, in the coming days, there will be rapid approval of peptide drug conjugates in treating cancers due to the robust clinical pipeline of drugs. Major driving factors of peptide–drug conjugates (PDCs) market are the increasing need for therapeutic drugs, high prevalence of cancer diseases, rising number of clinical trials, and increasing investments by key players to develop promising therapies. Furthermore, advanced medical technologies, population growth, and the growing number of health-conscious people enhance the market growth.
However, the high-cost treatments, complex procedures, and lack of strict government laws limit the market growth. In addition, the pipeline product approval process may get responsible for the delayed product launch, and production as a lot of clinical trials are progressive stages. FDA has approved very few pipeline products regarding peptide drug conjugates in the last five years, which will impact the market's forecasting period.
Market Segmentation
The Peptide Drug conjugate Market is segmented by products and indications. Product segmentation consists of Lutetium Lu 177 dotatate, Melflufen, ANG1005, BT1718, CBX-12, and Other Pipeline Products. By Indication, it is divided into Relapsed/Refractory Multiple Myeloma, Neuroendocrine Tumors (NETs), Gastric Cancers, Acromegaly, Ophthalmology, and Other Cancer Indications. Both segments play a vital role in the worldwide peptide drug conjugate market. The peptide–drug conjugates (PDCs) market is divided into North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. North America, followed by Europe, holds the maximum market share due to the high prevalence of cancer, increased research and development expenditure, and fast adaption of advanced technologies. Due to factors such as growing per capita healthcare spending, well-established research facilities for the development of innovative PDCs, preclinical research, and increased research on advanced drug discoveries, the United States has the largest market share in the North American region.
Competitive Landscape
Some major key players in the Peptide–Drug Conjugates (PDCs) Market:
- Novartis AG
- AstraZeneca
- Bicycle Therapeutics
- Cybrexa Therapeutics
- Esperance Pharmaceuticals
- Oncopeptides AB
- Pepgen Corporation
- Soricimed Biopharma
- Theratechnologies
- Pfizer Inc
- Validus Pharmaceuticals LLC
- Antisense Therapeutics
- Midatech Pharma PLC
- Ipsen Pharma
- Chiasma, Inc.
- Peptron, Inc.
- CRINETICS PHARMACEUTICALS
- Dauntless Pharmaceuticals
- Camurus AB
- Teva Pharmaceuticals Inc.
- Pharmaspur
- Aspireo Pharmaceuticals
- Ionis Pharmaceuticals Inc
- Midatech Pharma Plc
- Other Prominent Players
Peptide–Drug Conjugates (PDCs) Market Report Scope
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 696.2 Million |
|
Revenue forecast in 2031 |
USD 3113.7 Million |
|
Growth rate CAGR |
CAGR of 18.2 % from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
By Product, By Indication |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Novartis AG, AstraZeneca, Bicycle Therapeutics, Cybrexa Therapeutics, Esperance Pharmaceuticals, Oncopeptides AB, Pepgen Corporation, Soricimed Biopharma, Theratechnologies, Pfizer Inc, Validus Pharmaceuticals LLC, Antisense Therapeutics, Midatech Pharma PLC, Ipsen Pharma, Chiasma, Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc., Pharmaspur, Aspireo Pharmaceuticals, Ionis Pharmaceuticals Inc, Midatech Pharma Plc, and Other Prominent Players. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
